Advertisement Pharmaceutical Business review - Page 4 of 5233 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
March 14, 2025

FDA clears PDS Biotechnology’s Versamune MUC1 combo for mCRC

The US Food and Drug Administration (FDA) has granted clearance for PDS Biotechnology's investigational new drug (IND) application to assess Versamune MUC1 plus PDS01ADC for the treatment of unresectable, metastatic colorectal carcinoma (mCRC).

The trial will assess the combo in individuals with recurrent or mCRC. Credit: Louis Reed on Unsplash.